OverviewSuggest Edit

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.

OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.

TypePublic
Founded2008
HQSan Diego, US
Websiteotonomy.com

Latest Updates

Employees (est.) (Dec 2019)49
Revenue (FY, 2019)$600 K(-19%)
Share Price (Sept 2020)$3.9 (+5%)
Cybersecurity ratingBMore

Key People/Management at Otonomy

David A. Weber

David A. Weber

Chief Executive Officer, President and Board Member
Carla da Luz Boren

Carla da Luz Boren

General Counsel and Head of Human Resources
Julie D. Burgess

Julie D. Burgess

Vice President, Finance and Administration
Paul E. Cayer

Paul E. Cayer

Chief Financial & Business Officer
David Skarinsky

David Skarinsky

Vice President, Clinical
Barbara M. Finn

Barbara M. Finn

Vice President, Regulatory Affairs and Quality Assurance
Show more

Otonomy Office Locations

Otonomy has an office in San Diego
San Diego, US (HQ)
4796 Executive Dr
Show all (1)

Otonomy Financials and Metrics

Otonomy Revenue

Embed Graph
View revenue for all periods
Otonomy's revenue was reported to be $600 k in FY, 2019
USD

Revenue (Q2, 2020)

10.0k

Gross profit (Q2, 2020)

(501.0k)

Gross profit margin (Q2, 2020), %

(5010%)

Net income (Q2, 2020)

(11.5m)

EBIT (Q2, 2020)

(11.1m)

Market capitalization (14-Sept-2020)

189.5m

Closing stock price (14-Sept-2020)

3.9

Cash (30-Jun-2020)

32.0m

EV

175.8m
Otonomy's current market capitalization is $189.5 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

683.0k1.2m745.0k600.0k

Revenue growth, %

81%(40%)

Cost of goods sold

1.7m3.1m946.0k912.0k

Gross profit

(981.0k)(1.9m)(201.0k)(312.0k)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

24.2m18.5m33.6m25.2m

Accounts Receivable

91.0k107.0k108.0k48.0k

Prepaid Expenses

2.4m

Inventories

1.4m6.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

13.7m22.3m16.9m23.2m19.0m21.4m16.3m12.1m16.3m31.0m32.0m

Accounts Receivable

178.0k76.0k126.0k133.0k14.0k45.0k14.0k68.0k33.0k

Prepaid Expenses

1.5m3.7m2.2m1.5m

Inventories

1.2m1.2m1.2m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(110.6m)(90.1m)(50.4m)(44.7m)

Depreciation and Amortization

708.0k1.3m1.2m1.1m

Inventories

(1.4m)153.0k

Accounts Payable

(2.2m)(398.0k)68.0k127.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(27.1m)(71.3m)(11.4m)(25.0m)(37.5m)(12.0m)(23.7m)(33.7m)(11.8m)(23.2m)

Depreciation and Amortization

923.0k295.0k594.0k892.0k276.0k565.0k854.0k286.0k569.0k

Inventories

1.2m1.2m197.0k6.0k

Accounts Payable

212.0k1.3m138.0k1.5m(184.0k)321.0k123.0k837.0k(90.0k)(264.0k)(491.0k)
USDFY, 2016

Revenue/Employee

4.9k

Financial Leverage

1.1 x
Show all financial metrics

Otonomy Operating Metrics

FY, 2016

Patents Issued

88

Patents Pending

115

Phase III Trials Products

2

Products

1
Show all operating metrics

Otonomy Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Otonomy Online and Social Media Presence

Embed Graph

Otonomy News and Updates

Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Conference call and webcast today at 5 p.m. ET

Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program

Compound has potential to benefit patients with severe hearing loss Compound has potential to benefit patients with severe hearing loss

ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)

ROUND ROCK, Texas, June 17, 2020 /PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy, a...

Otonomy to Present at Raymond James 2020 Human Health Innovation Conference

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a company overv…

Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020

SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that due to the health, safety and travel concerns of stockholders and federal, state and local government…

Otonomy to Host Pipeline Program Update Conference Call and Webcast

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will host a conference call and webcast to review the status and timeline to results for the company’s …
Show more

Otonomy Blogs

Otonomy Provides Update on OTIVIDEX® Program

Otonomy Provides Update on OTIVIDEX® Program Content Import Mon, 07/06/2020 - 16:02 Otonomy Provides Update on OTIVIDEX® Program July 6, 2020 at 4:02 PM EDT This release is a backfill from a News Wire General Management will review th…

Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program

Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program Content Import Tue, 05/12/2020 - 08:02 Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss…

Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update

Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update Content Import Thu, 05/07/2020 - 07:32 Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update May 7, 2020 at 7:30 AM EDT This release is a backfill…

Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Content Import Thu, 02/27/2020 - 16:16 Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update February 27, 2020 at 4:15 PM EST …

Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update

SAN DIEGO , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2019 as well as provide a corporate

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

Preclinical results to be presented for GJB2 gene therapy hearing loss collaboration and OTO-510 program for cisplatin otoprotection SAN DIEGO , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for
Show more

Otonomy Frequently Asked Questions

  • When was Otonomy founded?

    Otonomy was founded in 2008.

  • Who are Otonomy key executives?

    Otonomy's key executives are David A. Weber, Carla da Luz Boren and Julie D. Burgess.

  • How many employees does Otonomy have?

    Otonomy has 49 employees.

  • What is Otonomy revenue?

    Latest Otonomy annual revenue is $600 k.

  • What is Otonomy revenue per employee?

    Latest Otonomy revenue per employee is $12.2 k.

  • Who are Otonomy competitors?

    Competitors of Otonomy include Seed, BeyondSpring and Inovio Pharmaceuticals.

  • Where is Otonomy headquarters?

    Otonomy headquarters is located at 4796 Executive Dr, San Diego.

  • Where are Otonomy offices?

    Otonomy has an office in San Diego.

  • How many offices does Otonomy have?

    Otonomy has 1 office.